Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

NCT03481816 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

NIH

Sponsor class

Conditions

Prostatic Neoplasms
Prostatic Cancer

Interventions

BIOLOGICAL: ETBX-071; adenoviral PSA vaccine
BIOLOGICAL: ETBX-061; adenoviral MUC1 vaccine
BIOLOGICAL: ETBX-051; adenoviral brachyury vaccine

Sponsor

National Cancer Institute (NCI)